johnson & johnson, page-31

GiddyUp, frankly this is incoherent nonsense. You just don't seem to get it, and your knowledge on the subject is a great deal less than you realise. These are cold hard facts, not twisting of statistics as you'd have it: Biotron's HCV trials have been in a relatively easy to treat population. BIT225 has modest potency against HCV at best. The results in the coinfected patients are a little more interesting but nothing more than you'd expect from any of the 3rd gen protease inhibitors or sofosbuvir, all substantially closer to or actually on the market. HCV DAA development is now focused on the difficult to treat end of the spectrum - cirrhotics and treatment failures. Biotron has gone nowhere near these patients to date. Do you not ask yourself why, during the most frenzied clinical trial period in the history of virology, has nobody yet come knocking on Biotron's door?
You are just the latest in a rather long line of Biotron cheerleaders who make quite outrageous pronouncements at the slightest hint of news from this rather non-communicative company, and who rabidly attack anyone who might have an alternate view. Most of the others are gone I see. Given that one you have have been having a go at recently is someone who actually has HCV, has been through treatment, and who has been no doubt been in long discussions with specialists about future options, you might actually credit that he knows something about this area, and not make idiotic suggestions that he is somehow in conspiracy with Gilead.
The most concerning thing of all is that there appear to be a number of people on this forum who actually think what you have to say has merit. I sincerely hope that they aren't making investment decisions based on it.